best glp-1 agonist companies Market Overview: Agonists and the Obesity Market | Blog GLP-1 Agonists Market Size, Share,
Description
But their impact is set to extend far beyond just blood sugar control
Perrini, L
Non-oral options like IUDs, implants, patches, vaginal rings, and injections bypass the digestive system entirely and are unaffected by GLP-1 medications
Discussion In our study, four principal findings emerged: (1) People receiving GLP-1 RA were older, more frequently female, and had a higher burden of endocrine, metabolic and gastrointestinal disorders compared to non GLP-1 RA Users
Bray GA, Frhbeck G, Ryan DH, Wilding JPH
